BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng H, Tang S, Lian X, Meng H, Gu X, Jiang J, Li X. The Differential Antitumor Activity of 5-Aza-2'-deoxycytidine in Prostate Cancer DU145, 22RV1, and LNCaP Cells. J Cancer 2021;12:5593-604. [PMID: 34405020 DOI: 10.7150/jca.56709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuan D, Fang Y, Chen W, Jiang K, Zhu G, Wang W, Zhang W, You G, Jia Z, Zhu J, Li T. ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress. Oxidative Medicine and Cellular Longevity 2022;2022:1-24. [DOI: 10.1155/2022/3611540] [Reference Citation Analysis]
2 Ke S, Liu Z, Wang Q, Zhai G, Shao H, Yu X, Guo J. FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway. Cancers (Basel) 2022;14:3915. [PMID: 36010909 DOI: 10.3390/cancers14163915] [Reference Citation Analysis]
3 Moreira-Silva F, Henrique R, Jerónimo C. From Therapy Resistance to Targeted Therapies in Prostate Cancer. Front Oncol 2022;12:877379. [PMID: 35686097 DOI: 10.3389/fonc.2022.877379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Herrero-aguayo V, Sáez-martínez P, Jiménez-vacas JM, Moreno-montilla MT, Montero-hidalgo AJ, Pérez-gómez JM, López-canovas JL, Porcel-pastrana F, Carrasco-valiente J, Anglada FJ, Gómez-gómez E, Yubero-serrano EM, Ibañez-costa A, Herrera-martínez AD, Sarmento-cabral A, Gahete MD, Luque RM. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Molecular Therapy - Nucleic Acids 2022;27:1164-1178. [DOI: 10.1016/j.omtn.2022.02.010] [Cited by in F6Publishing: 2] [Reference Citation Analysis]